Prefer Newsweek on Google to see more of our trusted coverage when you search. In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes ...

Geroscience shifts the medical focus from treating individual diseases to targeting the fundamental biological drivers of aging. Cellular senescence involves aging cells that cease division but ...

Molecular glue-focused biotech f5 Therapeutics has failed to stick around for the long haul, shuttering after six years, according to an announcement from the company’s CEO on LinkedIn. “The past few ...

The future of federally funded research at Harvard Medical School — supported by taxpayers and done in service to humanity — remains uncertain. Learn more. One of the most enduring goals in ...

Every time a cell divides, it must copy its entire genome so that each daughter cell inherits a complete set of DNA. During that process, enzymes known as polymerases race along the DNA to copy its ...

Debut has a new ingredient and is working with skin care brands on formulations. The biotech beauty company is launching DermCeutical EDL, a topical bioactive ingredient that claims to deliver ...

Burrowing shrimp are a well-documented native pest species in Willapa Bay that have been a nuisance to bottom-culture shellfish farmers for over a century. Methods for controlling shrimp populations ...

Arthur Herman’s op-ed, “America Is the Sole Superpower Again,” (Jan. 15) asserts that China is “sliding into a distant second place” in the battle for economic, military and technological supremacy.

PCWorld reports that Spotify offers a hidden “Basic” tier launched in mid-2024 for $10.99/month, providing music-only streaming without audiobooks or lossless audio. This plan requires existing ...

China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in the country. Experts say this could slow down American innovation in the biotech space. China's ...

A run of pharmaceutical mergers and acquisitions is fueling optimism that biotechnology venture capital is poised to rebound from its postpandemic slump. With $223 billion in biotech M&A deals ...